Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Diabetes medication adherence remains low among disadvantaged patients

A new study led by UCLA Health found that a large percentage of disadvantaged patients are not taking their diabetes medications consistently.

23 Sep 2026

GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline

The diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs may also help to slow decline in kidney function in people with type 2 diabetes and albuminuria (high protein levels in the urine), finds a large US study published by The BMJ today.

17 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

People with diabetes may have another reason to protect their cardiovascular health

Better cardiovascular health, measured using Life’s Essential 8, was associated with a lower risk of mild cognitive impairment among people with diabetes after accounting for genetic susceptibility. Associations with dementia varied by genetic risk, while higher LE8 scores were also linked to greater gray matter volume and lower white matter hyperintensity volume.

30 Aug 2026

Metformin cuts preterm birth risk among high-risk mothers

A common diabetes medication can reduce the risk of early and preterm births for mothers at high metabolic risk, according to new research led by Monash University.

26 Aug 2026

Scientists compared 51 longevity studies to see which aging biomarkers respond most reliably

Researchers analyzing 51 longitudinal intervention studies found that reliable generation 2+ DNA methylation biomarkers, particularly those predicting mortality or pace of aging, were the most responsive to interventions aimed at longevity or healthspan. Pharmacological and lifestyle interventions produced the strongest biomarker changes, but the authors cautioned that responsiveness does not yet establish these measures as validated surrogate endpoints for slower aging or longer life.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Type 2 diabetes mechanisms differ significantly based on patient BMI

Research published today in Diabetologia by Amsterdam UMC and the University of Ghana reveals that type 2 diabetes manifests in two fundamentally different ways depending on a patient's body mass index (BMI).

24 Aug 2026

Review outlines how SIRT3 protein regulates global metabolic disorders

A comprehensive review published in Engineering systematically outlines the regulatory capacity of silent information regulator 3 (SIRT3), a mitochondrial deacetylase termed the "head goose molecule", and its negentropic mechanism for intervening global metabolic disorders including type 2 diabetes, obesity, and steatotic liver disease.

21 Aug 2026

Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin.

6 Aug 2026

Early electroacupuncture intervention protects pancreatic function in prediabetes

Prediabetes refers to a metabolic state in which blood glucose is higher than normal but has not yet reached the diagnostic threshold for diabetes. It may involve impaired fasting glucose, impaired glucose tolerance, or elevated glycated hemoglobin A1c (HbA1c), and is closely associated with progressive β-cell dysfunction.

21 Jul 2026

Popular diabetes drugs do not alter the risk of developing a blinding eye condition

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

17 Jul 2026

Semaglutide dose may matter more than weight loss for heart health

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.

14 Jul 2026

Distinct gut microbiome signatures identify frailty in older women

Research reveals gut microbiome signatures linked to frailty in older women, highlighting microbial changes associated with mortality and physical decline.

13 Jul 2026

Nine gut bacteria linked to future type 2 diabetes risk

Research identifies specific gut microbes associated with future type 2 diabetes risk, emphasizing the impact of dietary fiber on microbiome health.

9 Jul 2026

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

1 Jul 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026